Pancreatic cancer can spread to the lungs, and it does so in roughly 5% to 12% of cases. The lungs are the second most common site of metastasis after the liver. When pancreatic cancer reaches the lungs or any distant organ, it is classified as stage IV, also called metastatic pancreatic cancer.
How Common Lung Metastases Are
Among patients with metastatic pancreatic cancer that has spread to a single organ, about 10% have isolated lung metastases at the time of diagnosis. Liver-only spread is far more common, accounting for roughly 76% of single-organ metastases, while lung-only cases represent about 20%. After surgery to remove the primary tumor, recurrence in the lungs occurs in approximately 11% to 13% of patients who develop a recurrence.
In rare cases, lung nodules are the very first sign that pancreatic cancer exists. There are documented cases of patients showing up with growing lung nodules on imaging while their abdominal scans look normal, only for a biopsy of the lung tissue to reveal pancreatic cancer cells. This is uncommon, but it underscores why doctors sometimes trace unexplained lung nodules back to the abdomen.
How Pancreatic Cancer Reaches the Lungs
Pancreatic cancer cells reach the lungs through the bloodstream. The process starts when cells in the primary tumor develop the ability to break away and invade surrounding tissue. Pancreatic tumors are notorious for producing a thick, fibrous barrier of tissue around them, and this dense environment actually helps select for the most aggressive cells, the ones capable of remodeling tissue and pushing through it.
Once in the bloodstream, pancreatic cancer cells survive by clustering together and interacting with blood components like platelets, which essentially shield them. When these circulating cells reach the lungs, they encounter a vast network of tiny blood vessels where they can lodge and begin growing. The cells then adapt to the lung’s specific environment, shifting their metabolism and suppressing the local immune response. Over time, these adaptations can produce tumors that behave quite differently from the original pancreatic tumor.
Symptoms of Lung Metastases
Small lung metastases from pancreatic cancer often cause no symptoms at all. They’re frequently discovered on routine staging CT scans rather than because a patient noticed something new. As nodules grow larger or multiply, you might develop a persistent cough, shortness of breath, or chest discomfort, but many patients with lung-only spread remain asymptomatic for months.
This is part of what makes detection tricky. If a staging CT of the chest shows small, benign-appearing nodules, follow-up imaging may not be prioritized. The nodules can grow slowly compared to liver metastases, sometimes creating a window where the spread goes unnoticed.
How Lung Spread Is Detected
CT scans of the chest, abdomen, and pelvis are the primary tool for identifying lung metastases. Pancreatic cancer that has spread to the lungs typically appears as bilateral pulmonary nodules, meaning small round spots in both lungs. When these nodules are found, doctors look at their size, number, and growth rate over time to assess whether they’re likely metastatic.
If CT findings are unclear, a PET scan can help. PET scans detect areas of high metabolic activity, and metastatic lung nodules from pancreatic cancer typically light up as metabolically active. A biopsy of a lung nodule can confirm whether the cells originated in the pancreas. Doctors also track a blood marker called CA 19-9. Patients with metastatic pancreatic cancer have significantly higher CA 19-9 levels than those without spread. A preoperative level above 336 units per milliliter has shown about 90% sensitivity and 80% specificity for predicting metastasis, making it a useful, though imperfect, screening signal.
Lung-Only Spread Has a Better Prognosis
This is the finding that may matter most to someone researching this topic: pancreatic cancer that spreads only to the lungs carries a meaningfully better prognosis than cancer that spreads to the liver. A real-world study of over 800 patients found median overall survival of 2.1 years for lung-only metastatic disease, compared to 1.3 years for liver-only metastatic disease. That survival advantage held regardless of which chemotherapy regimen patients received.
To put that in context, the overall median survival for advanced metastatic pancreatic cancer (all sites) is roughly 6 months, with a 5-year survival rate of only about 2%. So lung-only spread, while still serious, represents a relatively favorable subset of stage IV disease. Researchers believe this is partly because lung metastases from pancreatic cancer tend to grow more slowly and may reflect a biologically less aggressive form of the disease.
Treatment for Pancreatic Cancer With Lung Metastases
Pancreatic cancer that has spread to the lungs is treated with systemic chemotherapy, the same general approach used for metastatic disease at other sites. Current first-line options include combination regimens built around fluorouracil-based or gemcitabine-based drug cocktails. A newer regimen called NALIRIFOX was recently approved for first-line use, and updated European guidelines now include it alongside established options. Second-line treatments are also available when the first approach stops working.
For patients with isolated, limited lung metastases, some oncologists consider a more targeted approach. Because lung-only disease tends to behave less aggressively, selected patients may be evaluated for local treatments of the lung nodules in addition to chemotherapy. This remains an evolving area, and decisions are made case by case based on the number of nodules, their growth rate, and the patient’s overall condition.
The survival difference between lung-only and liver-only spread is consistent across treatment types. In patients receiving fluorouracil-based therapy, median survival was 2.1 years for lung-only disease versus 1.4 years for liver-only. With gemcitabine-based therapy, it was 2.1 years versus 1.2 years. This consistency suggests the survival advantage comes from the biology of the disease itself, not from one treatment working better for lung metastases.